Lineage Cell Therapeutics Q2 Earnings Call Highlights
· finance.yahoo.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimiza
During the question-and-answer session, Culley declined to provide more detailed information on the vessel sizes used in the company's Type 1 diabetes manufactu...